Company
Headquarters: Dijon, France
Employees: 85
CEO: Mr. Patrick Alexandre
€83.1 Million
EUR as of Jan. 1, 2025
US$86.4 Million
Company | Market Cap (USD) |
---|---|
Intuitive | $216.79 B |
EssilorLuxottica SA | $116.96 B |
Becton, Dickinson and Company | $69.74 B |
HOYA Corp | $45.26 B |
Alcon Inc. | $41.55 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Crossject SA has the following listings and related stock indices.
Stock: Euronext: ALCJ wb_incandescent
Stock: FSX: 74C wb_incandescent